BIORCHESTRA

company

About

BIORCHESTRA creates novel RNA-based therapeutics that will usher in a new era of treatment for neurodegenerative diseases.

Details

Last Funding Type
Series C
Last Funding Money Raised
$45M
Industries
Biopharma,Biotechnology,Health Care,Medical,Therapeutics
Founded date
Oct 18, 2016
Number Of Employee
1 - 10
Operating Status
Active
Legal Name
Biorchestra Co., Ltd.
Also Known As
바이오오케스트라

BIORCHESTRA is a biotech company that develops RNA-based therapeutics for treating neuroinflammatory diseases. They focus on changing the therapeutic paradigm from treating the symptoms to providing a fundamental cure for diseases. BIORCHESTRA develops neuroinflammatory disease therapeutics, with a particular emphasis on comprehensive patient care. BIORCHESTRA's complementary discovery platforms range from diagnosis to treatment monitoring.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$45M
BIORCHESTRA has raised a total of $45M in funding over 2 rounds. Their latest funding was raised on Feb 22, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 22, 2022 Series C $45M 12 Detail

Investors

Number of Lead Investors
Number of Investors
12
BIORCHESTRA is funded by 12 investors. GS Holdings and E&Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
GS Holdings Series C
E&Venture Partners Series C
Widwin Investment Series C
Chong Kun Dang Pharmaceutical Corp. Series C
Dayli Partners Series C
IMM Investment Series C
LSK Investment Series C
NH Investment & Securities Series C
Quantum Ventures Korea Series C
SBI Investment Series C

Employee Profiles

Number of Employee Profiles
2
BIORCHESTRA has 2 current employee profiles, including Executive Louis St.L. O'Dea
Executive
Executive